AnaptysBio Reports Positive Phase 2b Trial Results

An announcement from AnaptysBio ( (ANAB) ) is now available.

On June 3, 2025, AnaptysBio announced positive results from its Phase 2b RENOIR clinical trial for rosnilimab, a treatment targeting PD-1+ T cells in patients with moderate-to-severe rheumatoid arthritis. The trial demonstrated that rosnilimab achieved JAK-like efficacy with significant improvements in disease activity and remission rates, maintaining durable responses for at least two months off drug. The findings suggest rosnilimab’s potential for extended dosing intervals and its promising impact in the $20 billion U.S. RA market.

The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.

Spark’s Take on ANAB Stock

According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.

AnaptysBio’s overall stock score is primarily impacted by its strong revenue growth but significant profitability challenges. The technical indicators suggest moderate positive momentum, which is a positive factor for the stock. However, valuation concerns due to negative earnings and lack of dividend yield weigh down the score. Overall, the financial performance is the most significant factor affecting the score.

To see Spark’s full report on ANAB stock, click here.

More about AnaptysBio

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics.

Average Trading Volume: 733,649

Technical Sentiment Signal: Hold

Current Market Cap: $642.3M

For detailed information about ANAB stock, go to TipRanks’ Stock Analysis page.